Publication | Closed Access

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

UrologySurgical OncologyVersus ObservationGenitourinary CancerMedicineRenal PathologyImmunologyVaccine TrialTherapeutic VaccineRenal Cell CarcinomaVaccine EfficacyOncologyHigh Risk